2型糖尿病缓解:DiRECT/Counterweight-Plus体重管理项目2年内试验期与终生视角的成本效果分析
基于DiRECT试验(第1年2型糖尿病缓解率46%、第2年36%)的2年内成本效果分析显示,干预组2年平均总医疗费用3036英镑,对照组2420英镑,增量成本616英镑(95%CI -45至1269)。终生模型预测干预可获平均0.06个质量调整生命年(QALY)增益,人均终生节省1337英镑,干预在6年内转为节省成本。
要点
- 2年净缓解率32.3%,每获得1例缓解的成本为1907英镑。
- 干预组2年总费用较对照组增加616英镑,但其他医疗费用降低796英镑。
- 终生模型预测干预可获0.06 QALY增益并节省1337英镑,6年内转为节省成本。
核心结论
- 将糖尿病及其并发症缓解期带来的终生医疗费用节省纳入后,DiRECT干预预计在2型糖尿病成人中较标准照护更有效(QALY增益)且节省成本。
研究设计与样本
- 基于DiRECT试验的2年内试验期成本效果分析及终生成本效果模型。
主要发现
- 干预组2年平均总医疗费用3036英镑 vs 对照组2420英镑,增量成本616英镑(95%CI -45,1269)。
- 干预成本1411英镑(95%CI 1308,1511)被其他医疗费用降低796英镑(95%CI 150,1465)部分抵消,其中口服降糖药费用减少231英镑(95%CI 148,314)。
- 2年净缓解率32.3%(95%CI 23.5%,40.3%),每获得1例缓解的成本为1907英镑(95%CI下限:干预占优;上限:4212英镑)。
- 终生模型预测干预组平均QALY增益0.06(95%CI 0.04,0.09),人均终生总费用节省1337英镑(95%CI 674,2081),干预在6年内转为节省成本。
临床怎么用
- 作者认为,该结论在各种较不利的模型情景下均稳健,提供了强证据表明资源可以具有成本效果地转向支持通过DiRECT干预实现缓解。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Approximately 10% of total healthcare budgets worldwide are spent on treating diabetes and its complications, and budgets are increasing globally because of ageing populations and more expensive second-line medications. The aims of the study were to estimate the within-trial and lifetime cost-effectiveness of the weight management programme, which achieved 46% remissions of type 2 diabetes at year 1 and 36% at year 2 in the Diabetes Remission Clinical Trial (DiRECT). METHODS: Within-trial analysis assessed costs of the Counterweight-Plus intervention in DiRECT (including training, programme materials, practitioner appointments and low-energy diet), along with glucose-lowering and antihypertensive medications, and all routine healthcare contacts. Lifetime cost per quality-adjusted life-year (QALY) was estimated according to projected durations of remissions, assuming continued relapse rates as seen in year 2 of DiRECT and consequent life expectancy, quality of life and healthcare costs. RESULTS: Mean total 2 year healthcare costs for the intervention and control groups were £3036 and £2420, respectively: an incremental cost of £616 (95% CI -£45, £1269). Intervention costs (£1411; 95% CI £1308, £1511) were partially offset by lower other healthcare costs (£796; 95% CI £150, £1465), including reduced oral glucose-lowering medications by £231 (95% CI £148, £314). Net remission at 2 years was 32.3% (95% CI 23.5%, 40.3%), and cost per remission achieved was £1907 (lower 95% CI: intervention dominates; upper 95% CI: £4212). Over a lifetime horizon, the intervention was modelled to achieve a mean 0.06 (95% CI 0.04, 0.09) QALY gain for the DiRECT population and mean total lifetime cost savings per participant of £1337 (95% CI £674, £2081), with the intervention becoming cost-saving within 6 years. CONCLUSIONS/INTERPRETATION: Incorporating the lifetime healthcare cost savings due to periods of remission from diabetes and its complications, the DiRECT intervention is predicted to be both more effective (QALY gain) and cost-saving in adults with type 2 diabetes compared with standard care. This conclusion appears robust to various less favourable model scenarios, providing strong evidence that resources could be shifted cost-effectively to support achieving remissions with the DiRECT intervention. TRIAL REGISTRATION: ISRCTN03267836 Graphical abstract.
引用
- Xin Y, Davies A, Briggs A, et al. Type 2 diabetes remission: 2 year within-trial and lifetime-horizon cost-effectiveness of the Diabetes Remission Clinical Trial (DiRECT)/Counterweight-Plus weight management programme. Diabetologia. 2020. PMID: 32776237. doi:10.1007/s00125-020-05224-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。